Tin tức & Cập nhật
Xem bài viết Sản phụ khoa
Xem
Chỉ hiển thị Multimedia

KEYNOTE-522 final data boost pembrolizumab role in early breast cancer
09 Oct 2024
bởiAudrey Abella
Results from the phase III KEYNOTE-522 study presented at ESMO 2024 show a statistically significant and clinically meaningful improvement in overall survival (OS) with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemo alone for previously untreated, high-risk, early-stage triple-negative breast cancer (TNBC).
09 Oct 2024







